Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance  M.T. Christiansen, S.J. Hullegie, M. Schutten, K. Einer-Jensen, H.J. Tutill, J. Breuer, B.J.A. Rijnders  Clinical Microbiology and Infection  Volume 23, Issue 2, Pages 123.e1-123.e4 (February 2017) DOI: 10.1016/j.cmi.2016.09.018 Copyright © 2016 Terms and Conditions

FIG. 1 Relationship between HCV copy number identified in diagnostic sample (IU/mL × 2.7 = copies/mL) and mean read depth obtained across whole HCV genome. HCV, hepatitis C virus. Clinical Microbiology and Infection 2017 23, 123.e1-123.e4DOI: (10.1016/j.cmi.2016.09.018) Copyright © 2016 Terms and Conditions

FIG. 2 DAA resistance-associated mutation identified at baseline (n = 50) in acute HCV cohort. Vertical axis shows proportion of patients (%) in whom different mutations were identified. (a) Known DAA resistance-associated mutations in NS3/NS4a. (b) Known DAA resistance-associated mutations in NS5a. (c) Known DAA resistance-associated mutations in NS5b. DAA, direct-acting antiviral; HCV, hepatitis C virus. Dark gray: variant frequency >50%, light gray: variant frequency <50%. Clinical Microbiology and Infection 2017 23, 123.e1-123.e4DOI: (10.1016/j.cmi.2016.09.018) Copyright © 2016 Terms and Conditions